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Abstract
Background: To our knowledge, no study to date has investigated the prescribing patterns of
immunomodulatory agents (IMAs) in an outpatient setting in the United States. To address this
issue, we performed retrospective data analyses on National Ambulatory Medical Care Survey
(NAMCS) data for MS patient visits between 1998 and 2004.
Methods:  NAMCS data are a weighted estimate of the nationwide frequency of patients'
outpatient clinic visits. We analyzed NAMCS data in the following categories: (1) the proportion of
MS patient visits to neurologists, family practitioners or internists, (2) age/gender/race/geographical
distribution patterns in patient visits, and (3) the proportion of patients on IMA treatment among
established MS patients.
Results: There were an estimated 6.7 million multiple sclerosis (MS) patient visits to the clinics
between 1998–2004. Neurologists recorded the most patient visits, 50.7%. Patient visits were
mostly in the fourth and fifth decade age group (57.9%). The male to female ratio was 1:4. No
statistical evidence was observed for a decline or increase in IMA usage. About 62% patients visiting
neurologists and 92% seen by family practitioners/internists were not using IMAs. Our results
suggest that between the years 1998–2003, the use of interferon-1a tended to decline while the
use of interferon-1b and glatiramer acetate, increased.
Conclusion: Strategies that lead to improved use of IMAs in the management of MS in the
outpatient setting are needed.
Background
It is well established that MS is an inflammatory demyeli-
nating disease of the central nervous system that, after
trauma, is the second most common cause of neurologic
disability in young adults [1,2]. MS is a clinical diagnosis
and requires the integration of patient history with neuro-
logical examination, radiological evidence [3] and rele-
vant laboratory tests. It is accepted that MS is about twice
as common in women than in men [4]. The cause of MS
is unknown but environmental factors [5] and multiple
gene loci probably contribute to disease onset [6,7].
The course of MS depends in part on the type of disease
(relapsing-remitting or primary progressive) and site(s) of
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lesions. MS is a disease characterized by inter and intra-
patient variations, making prognosis difficult. Over time,
symptoms tend to become permanent and progressive
disability ensues. Since the early 1990s, six IMAs have
been approved by the US Federal Drug Administration
(FDA) for use in MS therapy: interferon-1b, (Betaseron) in
1993, interferon-1a (Avonex) and glatiramer acetate (GA,
Copaxone) in 1996, interferon-1a (Rebif) in 2002, mitox-
antrone (Novantrone) in 2000 and Tysabri (Natalizu-
mab) in 2006. Treatment with IMAs is thought to reduce
the frequency of relapses and slow disease progression as
shown in pivotal studies [8-11]. Economic modeling sug-
gests that treatment with IMAs is probably cost-effective
[12]. Although the costs of treatment remain high, loss of
productivity and direct care costs for individuals disabled
by MS are higher with worsening expanded disability sta-
tus scores (EDSS). Published data suggest that worsening
EDSS from < 3.5 to > 6.5 increase the mean total cost per
year of MS by a factor of 4.39 [13]. Therefore, analyses
about outpatient management practices could lead to
improvement in the treatment of MS patients and design
of better cost-effective treatment practices.
Methods
First initiated in 1973, NAMCS is a national probability
sample survey conducted in the United States and collects
data on the utilization of ambulatory medical care serv-
ices provided by office-based physicians. The National
Center for Health Statistics (NCHS) and the Centers for
Disease Control and Prevention (CDC; [14]) conducts
NAMCS and it is particularly designed to meet the need
for objective, reliable information about the provision
and use of ambulatory medical care services in the United
States. Findings are based on a sample of visits to non-fed-
erally employed office-based physicians who are prima-
rily engaged in direct patient care. Physicians in the
specialties of anesthesiology, pathology, and radiology
are excluded from the survey. The survey was conducted
annually from 1973 to 1981, then in 1985, and annually
again since 1989.
To collect data for NAMCS, specially trained interviewers
visit the physicians prior to their participation in the sur-
vey in order to provide them with survey materials and
instruct them on how to complete the forms. Data collec-
tion from the physician, rather than from the patient, pro-
vides an analytic base that expands information on
ambulatory care collected through other NCHS surveys.
Each physician is randomly assigned to a 1-week report-
ing period. During this period, data for a systematic ran-
dom sample of visits are recorded by the physician or
office staff on an encounter form provided for that pur-
pose. Data are obtained on patients' symptoms, physi-
cians' diagnoses, and medications ordered or provided.
The survey also provides statistics on the demographic
characteristics of patients and services provided, including
information on diagnostic procedures, patient manage-
ment, and planned future treatment.
The NAMCS survey contains data collected on individual
outpatient office visits and is then weighted to reflect
national estimates. The NAMCS data can be used to
address questions about patterns of reporting disease, dis-
ease-specific patient characteristics, and diagnoses. The
basic sampling unit for NAMCS is the physician-patient
encounter or outpatient visit.
For sample design, NAMCS uses a multi-stage approach
comprised of probability samples of primary sample units
(PSUs), physician practices within PSUs, and patient visits
within practices. Practices studied are those of non-feder-
ally employed physicians classified by the American Med-
ical Association (AMA) or American Orthopedic
Association (AOA) as "office-based, patient care". In addi-
tion, the practicing physicians had to meet four require-
ments as listed below. Furthermore, the sample design
describes that the design used was a multistage probabil-
ity sampling design, that the sample consisted of 112
PSUs that comprised a probability sub-sample of the PSUs
used in the NHIS survey (National Health Interview sur-
vey), that the second stage of the design consisted of a
probability sample of physicians within each PSU selected
from master files in the AMA or AOA, and finally that the
third stage involved randomly sampling the visits for a
physician using the above sampling rates as determined in
a pre-survey interview. The third stage involved two steps:
(1) the total physician sample was divided into 52
approximately equal sub-samples that were then ran-
domly assigned to one of the 52 weeks in a survey year;
and (2) a systematic random sample of visits was selected
by the physician during the assigned week. Patient record-
ing includes two forms, a patient log and a patient record
completed by the physician with the assistance of office
staff. The patient log is a sequential list of patients seen in
the office during the period 1998–2004.
To extrapolate to national estimates, each individual
record is assigned an inflation factor called the patient
visit weight, which is then used to predict the total
number of office visits made in the US. All estimates from
the NAMCS are related to the number of patient visits and
subject to sampling variability. An estimate is considered
reliable if it has a relative SE (sampling errors) of ≤ 30% of
the estimate, per NCHS standards. All data management
and analyses described were performed using SAS soft-
ware (Statistical Analysis System; SAS Institute; Cary, NC,
USA).
We focused on IMA treatment trends between 1998–2004
for all FDA approved IMA drugs. We chose to analyze dataBMC Medicine 2007, 5:6 http://www.biomedcentral.com/1741-7015/5/6
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on IMA use only among established MS patients as initial
visits to physicians could be part of a diagnostic work-up
and IMA use may not be initiated during the first visit. Vis-
its by established patients (return visits) were identified if
the patient was classified as having been seen before.
In order to test for the categorical association between var-
ious characteristics of the sample with year, chi-square
testing for homogeneity of proportions (Wald) was per-
formed. We accomplished this using the SAS 'Surveyfreq'
procedure and adjusted for the survey design in the
NAMCS, taking into consideration the NAMCS sample
weights, stratification, and clustering variables. Table 1
shows temporal trends in sample demographics and in
the use of FDA approved agents.
Logistic regression analysis was also performed to com-
pare the adjusted odds of IMA prescription between years,
with the dependent variable based on the probability of
an IMA prescription in MS return visits. The explanatory
variables were year (treated as categorical variable), age
group, gender, physician specialty, race, and insurance
type. The SAS procedure 'Surveylogistic' was used to calcu-
late odds ratios and survey-corrected confidence intervals.
Statistical significance of observed differences was set at p
< 0.05. In our study, MS patient visit was defined on the
basis of International Statistical Classification of Diseases
and Related Health Problems 9 (ICD-9) coding of 340.
Results
Table 1 shows the demographics for overall MS visits and
return visits by physician type. An estimated 6.7 million
patient visits (MS) occurred between 1998–2004 at a rate
of 3.4 visits/1,000 persons/year. The visit rate in the met-
ropolitan statistical area (MSA) versus non-MSAs was 2.73
to 0.64 per 1,000 persons, respectively. A total of 56% of
all MS visits in the MSA were to neurologists compared to
26% in non-MSAs. Women had a higher visit rate (4:1)
compared to men, and Caucasians had a higher visit rate
compared to African-Americans (90% versus 8%).
Up to 32% of all office visits with an MS diagnosis were
estimated to be to the patient's primary care physician.
Among visits made to offices in 2003, 52% listed private
insurance, followed by Medicare at 27%, and Medicaid at
10.5% (data not shown). Neurologists accounted for
50.7% MS patient visits while general/family practice and
internists combined provided for 33.7% of the visits.
Patient visits were highest in the West (29%) compared to
the Midwest (19.4%). Proportions for return visits to all
the three physician groups were very similar to the overall
MS visit proportions.
When compared by year, the proportion of visits for pri-
mary care physician (p < 0.0001), diagnostic/screen serv-
ices ordered/provided (p = 0.0182), versus visits to
neurologist (p = 0.0079), differed significantly. Figure 1
shows trends in physician return visits for patients with a
diagnosis of MS, on the y-axis. These trends suggest there
was a decrease in the proportion of visits involving neu-
rologists from 1998 to 2004 and that there was a greater
likelihood diagnostic/screening service provided/ordered
during that period. The trend with regards to primary care
providers appears to have a substantial variation from
year to year.
Of the FDA-approved agents for MS, use of Avonex
appeared to exhibit a downward trend (27% in 1998 to
Table 1: Demographics for overall and return MS visits to neurologists (N), family practitioners (FP), and internists (I)
Overall (1998–2004) Overall MS visit rate per year per 1,000 US residents* Return MS visits to N, FP, and I (1998–2004)
Estimated no. of MS visits 6,682,288 3.38 4,959,782
Specialty
Neurologists 50.7% 1.72 59.6%
Family practitioners 20.7% 0.70 25.6%
Internists 11.0% 0.37 14.8%
Other 17.6 % 0.60 -
Gender: females 77.6% 2.63 77.1%
Race: Caucasian 90.4% 3.06 88.9%
Metropolitan status: (MSA) 80.8% 2.73 76.5%
Age group
0–19 2.0% 0.07 0.88%
20–39 20.8% 0.70 18.4%
40–59 57.9% 1.96 59.5%
60+ 19.3% 0.65 21.2%
Primary care physician 32.3% 1.09 39.8%
Region
Northeast 26.7% 0.90 25.1%
Midwest 19.4% 0.66 20.1%
South 25.1% 0.85 28.2%
West 28.9% 0.98 26.5%
* Based on 2000 census population.BMC Medicine 2007, 5:6 http://www.biomedcentral.com/1741-7015/5/6
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11% in 2000), whereas that of Copaxone and Betaseron
appeared to show an upward trend. However none of
these trends were significant at 0.05 when using a chi-
square test to detect a difference in proportions. When
combined, IMA use did not show any statistically signifi-
cant trend (p = 0.5113).
Among the three physician groups, neurologists
accounted for 78% of Avonex, and 100% of Betaseron/
Copaxone prescriptions. Figure 2 shows the estimated
IMA prescription percentages for return visits with a diag-
nosis of MS. Internists and family medicine practitioners
prescribed 12% and 11% of Avonex but negligible num-
bers for Betaseron and Copaxone. Neurologists also pre-
scribed IMAs more often than the other two groups
combined (38% versus 9%, p = < 0.0001).
Table 2 shows logistic regression analysis predicting the
probability of IMA prescription during a visit. Although
the adjusted odds of IMA prescription remained equal to
or smaller for all years compared to 1998, the results were
not statistically significant. The odds for age group 40–59
was statistically significant when compared to the 20–30
age group (OR = 0.40). In addition, female patients were
more likely to be on IMAs (OR = 1.98), and patients on
Medicaid insurance were less likely to be prescribed IMAs
(OR = 0.34).
Discussion
The NAMCS data provide information about MS patients
and trends in their outpatient management. NAMCS data
are used by public health policy makers, health services
researchers, medical schools, physician associations and
epidemiologists to describe and understand the changes
that occur in medical care requirements and practices. It is
important to understand that data are constructed on a
sample of visits rather than a sample of people. The
NAMCS surveys basically provide national estimates.
Apart from obtaining basic data concerning age, gender,
and geographical distribution of MS patients across the
US, our goal was to evaluate the proportion of patients
with an established diagnosis of MS receiving FDA-
approved medications. We also studied how treatment
was influenced by type of treating physician, i.e., neurolo-
Trends in physician return visits with a diagnosis of MS, NAMCS data, 1998–2004 Figure 1
Trends in physician return visits with a diagnosis of MS, NAMCS data, 1998–2004. Y-axis depicts all returning patients with MS 
diagnosis.
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gist, internist or family medicine practitioner and geo-
graphic location.
According to the national MS society, the incidence of MS
in the US is about 1/1,000; we found an estimated 6.7
million MS outpatient visits occurred between 1998–
2004, or 3.4 visits/1,000 patients/year. We found that
women were seen four times as often as men, and Cauca-
sians > non-Caucasians, a trend that perhaps points to
increased prevalence among Caucasian women more than
any one ethnic group. Not surprisingly, neurologists pre-
scribed IMAs more often (21%) than family practitioners/
internists (8%). The majority of patients seeing family
practitioners or internists were on no IMA therapy. The
use of Avonex declined from 1998 and could have been
triggered by the perception that it has sub-optimal dose/
frequency [15,16]. The fact that a greater proportion of MS
visits (56%) were directed to neurologists in MSAs than in
non-MSAs (26%, p < 0.0001) perhaps reflects better
patient access to specialty care services in MSAs.
MS is among the leading causes of disability in young
adults [17]. The natural history of MS suggests that disa-
bility accumulates over time and the use of IMAs reduces
the frequency of new enhancing lesions, relapses and rate
of cerebral atrophy [18-20]. The advent of Betaseron,
Avonex and Copaxone represents a major breakthrough
in MS therapy and three large placebo-controlled, double-
blind studies have demonstrated efficacy [8-10]. Although
each clinical trial had unique features and differences that
make direct comparisons erroneous, published results
demonstrate a clear benefit of IMAs for decreasing
relapses and probability of sustained clinical disability
progression in patients with MS [21]. Additionally, data
from Controlled High Risk Avonex Multiple Sclerosis
Study (CHAMPS; [22]) and Early Treatment of MS
(ETOMS; [23]) studies suggest that initiating treatment
with Avonex or Rebif early could perhaps delay the devel-
opment of clinically definite multiple sclerosis. More
recently, Betaseron has been shown to be of benefit in
clinically isolated syndromes [24] while Rebif has been
shown to be superior to Avonex in the EVIDENCE (Evi-
Estimated IMA prescription percentages in return visits, NAMCS data, 1998–2004 Figure 2
Estimated IMA prescription percentages in return visits, NAMCS data, 1998–2004.
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dence of Interferon Dose-Response: European North
American Comparative Efficacy) study [25].
The NAMCS data analysis shows that 62% of established
MS patients seeing neurologists and 92% of those seeing
family medicine practitioners or internists were not being
treated with IMAs. The increased use of IMAs by neurolo-
gists probably reflects greater awareness of the drugs'
availability and their use by specialists who more often
treat patients with MS. Additionally, an association
between co-payments and IMA use in patients with pri-
vate-sector health plans may have a role (26). It would be
important to test whether reducing co-payments for MS
treatment would reduce the use of other health care serv-
ices through better MS treatment that modifies the course
of illness.
Limitations in our data analyses
The reasons for the generally low IMA utilization rate were
not obvious from analysis of the NAMCS data. It is plau-
sible that some individuals with MS have mild symptoms
during the initial phase of the illness, and either the
patient or the physician could decide to defer treatment.
Other factors for the low IMA use could be a relatively new
MS therapy in the market whose risk/benefit ratio is not
obviously evident, patients' lack of awareness about the
pros and cons of treatment, being advised by their physi-
cian that they did not meet criteria for taking it, differ-
ences in physician communication styles, physician
beliefs about the appropriateness of the drug, physician
perceptions about internal organizational constraints and
policies regarding its use, or some combination of these
factors. Academic neurologists were not excluded from
this survey – the NAMCS data are collected on individual
outpatient office visits and are then weighted to reflect
national estimates.
Because our data are drawn from a survey of physician
office visits for MS, data drawn from tertiary care clinics or
advocacy organizations may have been excluded. In addi-
tion, logistic regression analysis revealed no association
between IMA prescription and type of insurance, although
this was not one of our aims of our study.
The possible impact of unmeasured co-variables cannot
be ignored in interpreting our findings particularly as
applied to IMA use among non-neurologists. Addition-
ally, data on longitudinal follow-up of patients are una-
vailable in the NAMCS databases, a significant drawback.
The reason for decline in Avonex use between 1998–2000
remains unexplained and could represent sample varia-
tion. Analysis of newer data could determine how the use
of IMAs is evolving.
To improve IMA prescription practices, a possible solu-
tion would be to pinpoint variations in service delivery
and to initiate longitudinal follow-up studies. Above all,
strategies for educating both neurologists and non-neu-
rologists about the benefits of initiating IMA use in MS
patients and in continuing their use remain critical to
improving long-term patient outcomes in the treatment of
MS.
Conclusion
Strategies that lead to improved use of IMAs in the man-
agement of MS in the outpatient setting are needed. Our
study found that a significant proportion of established
MS patients visiting either neurologists or family medi-
Table 2: Logistic regression analysis predicting the probability of IMA prescription during a visit
Odds ratio 95% Confidence intervals
2004 0.43 (0.13, 1.48)
2003 0.96 (0.35, 2.64)
2002 0.89 (0.24, 3.32)
2001 0.75 (0.23, 2.47)
2000 0.47 (0.13, 1.63)
1999 0.33 (0.09, 1.30)
1998 Reference -
0–19 0.39 (0.06, 2.50)
20–39 Reference -
40–59 0.40 (0.21, 0.79)
60+ 0.42 (0.15, 1.15)
Female 1.98 (1.09, 3.58)
Neurologist 6.69 (2.87, 15.59)
Caucasian 0.62 (0.31, 1.22)
Private insurance Reference -
Medicare insurance 0.86 (0.43, 1.72)
Medicaid insurance 0.34 (0.11, 0.99)
Other insurance 1.26 (0.47, 3.38)BMC Medicine 2007, 5:6 http://www.biomedcentral.com/1741-7015/5/6
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cine practitioners/internists were not using IMAs. Despite
limitations inherent in our study, outpatient management
of MS remains far from ideal in the USA.
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